A test leveraging a unique RNA signature pre-transplant that provides information about post-transplant graft function and immunosuppression status in deceased-donor kidney transplant recipients.
An NGS-based assay developed for clinicians and HLA laboratories to detect cell-free DNA in human plasma samples. This assay provides high sensitivity, with minimal hands-on time and results in as little as 24 hours.
Innovative software leveraging gene expression data from biopsied heart and kidney tissue. This service can provide information that can supplement diagnoses of allograft injury via histopathology and other parameters.
Noninvasive urine-based test that can detect the CXCL10 chemokine in human urine samples for kidney transplantation. Multiple studies have shown that elevated CXCL10 is associated with inflammation and early graft dysfunction.
Qualitative assay that detects 12 genes from exosomal RNA, with unique signatures for injury type (humoral versus antibodymediated). Studies have demonstrated this assay’s ability to support early, accurate detection of allograft dysfunction in kidney transplant recipients.
HLA donor specific antibodies (DSAs) are linked to transplant rejection. Our reliable, high-sensitivity single-bead assays offer optimal antibody monitoring for better transplant care.
Designed to provide accurate and sensitive detection of microchimerism levels in stem cell transplant samples, the One Lambda Devyser Chimerism NGS assay is an ideal choice for HLA and molecular core labs associated with HSCT Programs.
Not all tests or products are CE marked or have 510(k) clearance for sale in the U.S. Availability of tests or products in each country depends on local regulatory marketing authorization status. One Lambda Pre-Transplant Risk Assessment Assay, One Lambda Exosomes kidney Transplant Assay and One Lambda CXCL10 Assay are Laboratory Developed Tests (LDTs) offered, developed and validated through One Lambda Laboratories. One Lambda Exosomes kidney Transplant Assay incorporates ExoTRU™ technology from Exosomes Diagnostics, a Bio-Techne brand. MMDx Heart and MMDx Kidney are LDTs offered, developed and validated through Kashi Clinical Laboratories. These LDTs are used for clinical purposes by the CLIA certified laboratory performing the test. Each of these tests have not been cleared or approved by the FDA or CE marked in the EU as an in vitro diagnostic test.
Dvysr is a trademark of Devyser AB. MMDx and Molecular Microscope are trademarks of Transcriptome Sciences Inc.